We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




First European Company Obtains CE-IVD Marking for Next Generation Sequencing in Routine Testing

By LabMedica International staff writers
Posted on 16 Sep 2014
Print article
For the first time, a European company, Sophia Genetics (Lausanne
Switzerland), has obtained the CE-IVD mark for clinical use of Next Generation Sequencing (NGS) bioinformatics pipeline for routine genetic testing.

Sophia Genetics received this CE-IVD mark shortly after receiving ISO 13485 accreditation. ISO 13485:2003 specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet applicable customer and regulatory requirements. The CE-IVD marking indicates that an IVD device complies with the European In Vitro Diagnostics Directive (98/79/EC), and that the device may be legally commercialized and distributed in the EU. This quality assurance certification represents an important step in raising standards, and brings Sophia Genetics’ leading Data Driven Medicine platform to a wider market.

The certification also means that Sophia Genetics’ proven quality assurance methodology can now be leveraged by clinical laboratories to meet their own quality assurance requirements. Using Sophia Genetics’ service, clinical laboratories gain access to quality assurance expertise, facilitating both cost-saving and time-efficient filing for ISO 15189 accreditation and compliance with the new CE-IVD Directive. Sophia Genetics will seek the CE-IVD marking for all genetic tests it supports.

Jurgi Camblong, CEO of Sophia Genetics, said, “The barrier to wider adoption of NGS data for the routine genetic testing of patients has historically been the challenge associated with analyzing data. At Sophia Genetics we understand the complexity of NGS data and the need to analyze this data to a clinical standard. We have designed solutions to address even the most difficult data analysis problems that existing bioinformatics software programs are not able to solve, making NGS genetic testing much simpler, faster, and easier for our lab customers.”

Related Links:

Sophia Genetics 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.